CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has synthesized prodrugs of deuterated baloxavir marboxil derivatives acting as cap-dependent endonuclease (CEN) (influenza virus) inhibitors reported to be useful for the treatment of influenza viral infections.